650 Albany Street, Room 130
Boston, MA 02118
is a Boston-based biotechnology company focused on the discovery and development of novel antimicrobial agents. Our drug discovery pipeline includes a drug discovery platform focused on sterilizing antifungal treatments, capable of taking the standard “static” antifungals beyond “cidal”, both killing actively growing pathogens and eliminating persister populations that are responsible for treatment failure and recurrence. We also have programs for the identification of narrow spectrum antibiotics specifically targeting H. pylori, the cause of gastric and duodenal ulcers. Founded in 2006, the Arietis approach and technology are totally novel and will bridge an important gap in antimicrobial therapeutics. Arietis has forged productive alliances and partnerships within the biotechnology community that advance our capacity to develop effective drug products. We are committed to providing innovative solutions to the problem of persistent infections, thereby decreasing the burden on health systems worldwide.
The company was created based on technology invented by its founder, Professor Kim Lewis, Director of the Antimicrobial Center at Northeastern University. Arietis is led by Dr. Thomas A. Dahl, CEO, an experienced business executive and drug developer, and benefits from the drug discovery and development insights of Dr. Kenneth Coleman, Chief Scientific Officer.
Arietis is pleased to announce the awarding this year of Phase 1 and Fast-Track SBIR grants from the National Institutes of Health. These grants will provide support for our R&D efforts through June, 2016.